A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 10 Jun 2017 Biomarkers information updated
- 22 Dec 2016 Planned End Date changed from 1 Jan 2021 to 1 Jun 2021.
- 22 Dec 2016 Planned primary completion date changed from 1 Jan 2021 to 1 Jun 2021.